Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age40-99
SponsorMassachusetts General Hospital
About this trial
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).
This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).
Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
Eligibility criteria
Qualifiers
Between the ages of 40-99
Native English speakers
Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
Patients with PPA will be asked to bring a study partner to all visits
Disqualifiers
History of head trauma involving loss of consciousness or alteration in consciousness
Another major neurologic or psychiatric condition
Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
Trial design
Treatments tested in this trial
- Active rTMS
- Sham rTMS
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Harvard Medical School (HMS and HSDM)
Sponsor institution
Source ClinicalTrials.gov